Adavosertib

An article about the drug Adavosertib

Adavosertib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Adavosertib is a small molecule inhibitor of the WEE1 kinase, a protein that plays a critical role in the regulation of the cell cycle. It is being investigated for its potential use in the treatment of various types of cancer.

Mechanism of Action

Adavosertib functions by inhibiting the activity of the WEE1 kinase, which is involved in the G2/M checkpoint of the cell cycle. This checkpoint is crucial for ensuring that cells do not enter mitosis with damaged DNA. By inhibiting WEE1, adavosertib disrupts this checkpoint, leading to cell cycle arrest and potentially enhancing the effects of DNA-damaging agents such as chemotherapy and radiation therapy.

Clinical Development

Adavosertib is currently undergoing clinical trials to evaluate its efficacy and safety in combination with other cancer therapies. It has shown promise in preclinical studies and early-phase clinical trials, particularly in cancers with p53 mutations, where the G1 checkpoint is compromised, making the G2/M checkpoint more critical.

Potential Applications

The primary focus of adavosertib research is in the treatment of ovarian cancer, breast cancer, and other solid tumors. Its ability to sensitize cancer cells to DNA damage makes it a promising candidate for combination therapy with existing treatments.

Side Effects

As with many cancer therapies, adavosertib can cause a range of side effects. Commonly reported side effects include nausea, fatigue, and hematological toxicity. Ongoing clinical trials continue to monitor and evaluate the safety profile of adavosertib.

Related pages

• WEE1 kinase
• Cell cycle
• Cancer treatment
• Chemotherapy

Gallery

• 
  Chemical structure of Adavosertib